Short answer
Psilocybin shows real promise for addiction, particularly alcohol use disorder. In a 2022 randomized, placebo-controlled trial, people who received psilocybin with therapy drank heavily on 9.7% of days over eight months, compared with 23.6% for placebo. A small 2014 pilot in smokers reported 80% abstinence at six months, but it had no control group. Larger trials are needed before psilocybin can be called an addiction treatment.
Key takeaways
- Alcohol: a 93-person randomized trial found heavy drinking days dropped 83% with psilocybin versus 51% with placebo.
- Smoking: 12 of 15 people in a pilot study were abstinent six months later, confirmed by lab tests.
- Opioids and stimulants: little psilocybin data so far.
- Psilocybin itself has low abuse potential.
Alcohol use disorder
The strongest addiction data comes from a 2022 trial led by Michael Bogenschutz at NYU and published in JAMA Psychiatry. Ninety-three adults with alcohol dependence received 12 weeks of therapy plus two medication sessions, either psilocybin or an antihistamine placebo.1
| Outcome over 32 weeks | Psilocybin | Placebo |
|---|---|---|
| Share of days with heavy drinking | 9.7% | 23.6% |
| Reduction in heavy drinking days from baseline | 83% | 51% |
| Abstinent about seven months after final dose | 48% | 24% |
Source: Bogenschutz and colleagues, 2022, as reported by The Hospitalist.12
Notice that the placebo group improved a lot too. That's the therapy working, and it's why controlled trials matter. Psilocybin roughly doubled the effect.
Smoking
In a 2014 Johns Hopkins pilot, 15 long-term smokers received psilocybin along with a structured quit-smoking program. Six months later, 12 of the 15 were abstinent, confirmed by breath and urine tests.3 For comparison, the best existing quit-smoking medications typically help well under half of people stay quit at six months.
The caveat is big: 15 people, no control group. A larger randomized trial comparing psilocybin with nicotine patches has been underway at Johns Hopkins. Until results like that are published in full, smoking cessation stays in the promising column.
Opioids, stimulants, and other addictions
There's very little controlled psilocybin research in opioid, cocaine, or methamphetamine addiction yet. Federal attention in 2026 has focused more on ibogaine for opioid use disorder, including through a new HHS and VA agreement, despite ibogaine's known heart risks.5
Why might it work?
Addiction is, among other things, a deeply grooved habit of thought and behavior. One theory is that psilocybin temporarily loosens those grooves, giving people a window to see their patterns differently and build new ones with therapy. Participants in these trials often describe insights about why they drank or smoked, and a renewed sense of what matters to them. It also helps that psilocybin itself has low abuse potential and no withdrawal syndrome.4 See are shrooms addictive?
How to get involved
Psilocybin isn't approved for any addiction. If you're struggling, evidence-based treatments are available now, and you can call the SAMHSA National Helpline at 1-800-662-4357. If you're interested in psilocybin research, search ClinicalTrials.gov for active studies.
Common questions
Can psilocybin cure alcoholism?
No treatment cures alcohol use disorder, but the 2022 trial results are among the strongest for any new approach in years. Psilocybin was given with psychotherapy, and that combination is what was tested.
Is psilocybin used for opioid addiction?
Not much yet. Federal psychedelic research on opioid addiction in 2026 is focused more on ibogaine, a different psychedelic with serious heart risks. Psilocybin research in opioid use disorder is at an early stage.
Isn't it risky to treat addiction with a drug?
It's a fair question. Psilocybin's abuse potential is low, it's given only a few times under supervision in these studies, and it doesn't cause physical dependence. That's very different from replacing one daily drug with another.
Sources
- Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 2022. doi.org/10.1001/jamapsychiatry.2022.2096
- The Hospitalist. Psychedelic drug therapy a potential breakthrough for alcohol dependence. 2022. the-hospitalist.org
- Johnson MW, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology. 2014. doi.org/10.1177/0269881114548296
- Johnson MW, et al. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018. doi.org/10.1016/j.neuropharm.2018.05.012
- U.S. Department of Health and Human Services. HHS, VA partner to advance psychedelic therapies for veterans. July 13, 2026. hhs.gov
This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.